Literature DB >> 18497517

Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia.

Thomas Lowe1, Thehang Luu, Jeannie Shen, Smita Bhatia, Stephen Shibata, Anthony Stein, George Somlo.   

Abstract

BACKGROUND: Over the years, the prognosis following treatment of a primary cancer has significantly improved. However, the growing population of these cancer survivors has led to the realization of multiple longterm complications secondary to their treatment. One of the most devastating long-term complications is the development of a second malignancy. CASE REPORTS: We report here the case of a 34-year-old man who developed stage IIB node-positive breast cancer almost 15 years following total body irradiation and allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia. To our knowledge, this is only the second report of a male breast cancer following allogeneic bone marrow transplantation (BMT).
CONCLUSION: Survivors of primary cancer need lifelong monitoring for complications from their initial therapy. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18497517     DOI: 10.1159/000121395

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  4 in total

1.  Invasive Lobular Carcinoma of the Male Breast: A Rare Histology in an Uncommon Disease.

Authors:  Susanne Briest; Russell Vang; Kyle Terrell; Leisha Emens; Julie R Lange
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

2.  A rare complication resulting in a rare disease: radiation-induced male breast cancer.

Authors:  Jamila Alazhri; Constantine Saclarides; Eli Avisar
Journal:  BMJ Case Rep       Date:  2016-04-15

Review 3.  Male Breast Cancer.

Authors:  Metin Yalaza; Aydın İnan; Mikdat Bozer
Journal:  J Breast Health       Date:  2016-01-01

Review 4.  Male breast cancer: an update in diagnosis, treatment and molecular profiling.

Authors:  Susan Onami; Melanie Ozaki; Joanne E Mortimer; Sumanta Kumar Pal
Journal:  Maturitas       Date:  2010-02-06       Impact factor: 4.342

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.